Emergency deployment of genetically engineered veterinary vaccines in Europe

Bahar Ramezanpour, Jean de Foucauld, Jeroen Kortekaas*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

On the 9th of November 2015, preceding the World Veterinary Vaccine Congress, a workshop was held to discuss how veterinary vaccines can be deployed more rapidly to appropriately respond to future epizootics in Europe. Considering their potential and unprecedented suitability for surge production, the workshop focussed on vaccines based on genetically engineered viruses and replicon particles. The workshop was attended by academics and representatives from leading pharmaceutical companies, regulatory experts, the European Medicines Agency and the European Commission. We here outline the present regulatory pathways for genetically engineered vaccines in Europe and describe the incentive for the organization of the pre-congress workshop. The participants agreed that existing European regulations on the deliberate release of genetically engineered vaccines into the environment should be updated to facilitate quick deployment of these vaccines in emergency situations.

Original languageEnglish
Pages (from-to)3435-3440
JournalVaccine
Volume34
Issue number30
DOIs
Publication statusPublished - 2016

Fingerprint

Emergencies
Vaccines
vaccines
Education
replicon
Replicon
Virion
Motivation
medicine
Organizations
drugs
viruses
Pharmaceutical Preparations

Keywords

  • Directive
  • Europe
  • Genetically engineered
  • Live-attenuated
  • Replicon
  • Reverse genetics
  • Vaccine
  • Virus

Cite this

Ramezanpour, Bahar ; de Foucauld, Jean ; Kortekaas, Jeroen. / Emergency deployment of genetically engineered veterinary vaccines in Europe. In: Vaccine. 2016 ; Vol. 34, No. 30. pp. 3435-3440.
@article{826765630492422a95d215e2be89f72e,
title = "Emergency deployment of genetically engineered veterinary vaccines in Europe",
abstract = "On the 9th of November 2015, preceding the World Veterinary Vaccine Congress, a workshop was held to discuss how veterinary vaccines can be deployed more rapidly to appropriately respond to future epizootics in Europe. Considering their potential and unprecedented suitability for surge production, the workshop focussed on vaccines based on genetically engineered viruses and replicon particles. The workshop was attended by academics and representatives from leading pharmaceutical companies, regulatory experts, the European Medicines Agency and the European Commission. We here outline the present regulatory pathways for genetically engineered vaccines in Europe and describe the incentive for the organization of the pre-congress workshop. The participants agreed that existing European regulations on the deliberate release of genetically engineered vaccines into the environment should be updated to facilitate quick deployment of these vaccines in emergency situations.",
keywords = "Directive, Europe, Genetically engineered, Live-attenuated, Replicon, Reverse genetics, Vaccine, Virus",
author = "Bahar Ramezanpour and {de Foucauld}, Jean and Jeroen Kortekaas",
year = "2016",
doi = "10.1016/j.vaccine.2016.05.013",
language = "English",
volume = "34",
pages = "3435--3440",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "30",

}

Emergency deployment of genetically engineered veterinary vaccines in Europe. / Ramezanpour, Bahar; de Foucauld, Jean; Kortekaas, Jeroen.

In: Vaccine, Vol. 34, No. 30, 2016, p. 3435-3440.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Emergency deployment of genetically engineered veterinary vaccines in Europe

AU - Ramezanpour, Bahar

AU - de Foucauld, Jean

AU - Kortekaas, Jeroen

PY - 2016

Y1 - 2016

N2 - On the 9th of November 2015, preceding the World Veterinary Vaccine Congress, a workshop was held to discuss how veterinary vaccines can be deployed more rapidly to appropriately respond to future epizootics in Europe. Considering their potential and unprecedented suitability for surge production, the workshop focussed on vaccines based on genetically engineered viruses and replicon particles. The workshop was attended by academics and representatives from leading pharmaceutical companies, regulatory experts, the European Medicines Agency and the European Commission. We here outline the present regulatory pathways for genetically engineered vaccines in Europe and describe the incentive for the organization of the pre-congress workshop. The participants agreed that existing European regulations on the deliberate release of genetically engineered vaccines into the environment should be updated to facilitate quick deployment of these vaccines in emergency situations.

AB - On the 9th of November 2015, preceding the World Veterinary Vaccine Congress, a workshop was held to discuss how veterinary vaccines can be deployed more rapidly to appropriately respond to future epizootics in Europe. Considering their potential and unprecedented suitability for surge production, the workshop focussed on vaccines based on genetically engineered viruses and replicon particles. The workshop was attended by academics and representatives from leading pharmaceutical companies, regulatory experts, the European Medicines Agency and the European Commission. We here outline the present regulatory pathways for genetically engineered vaccines in Europe and describe the incentive for the organization of the pre-congress workshop. The participants agreed that existing European regulations on the deliberate release of genetically engineered vaccines into the environment should be updated to facilitate quick deployment of these vaccines in emergency situations.

KW - Directive

KW - Europe

KW - Genetically engineered

KW - Live-attenuated

KW - Replicon

KW - Reverse genetics

KW - Vaccine

KW - Virus

U2 - 10.1016/j.vaccine.2016.05.013

DO - 10.1016/j.vaccine.2016.05.013

M3 - Article

VL - 34

SP - 3435

EP - 3440

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -